Trial Profile
GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs KUR 501 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Neuroblastoma
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms GINAKIT2
- 27 Jul 2023 Planned End Date changed from 10 Aug 2034 to 10 Aug 2040.
- 27 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.
- 15 May 2023 According to media release, results from this study was published in Nature Medicine.